© 2019 Matrivax Research and Development Corporation

650 Albany Street, Suite 117, Boston, MA 02118

Tel: 617-3587640

  • Nicole Ruggiero

Please join us at World Vaccine Congress 2020, in Washington D.C.

April 6, 2020 at 10:00


The Centers for Disease Control (CDC) has named C. difficile infections an urgent public health threat and the leading hospital-acquired infection in the U.S. With an enormous human toll, and significant health care costs, there is a clear need to prevent and treat this infection. Join us in this workshop as we hear from experts on their promising approaches to tackle the infection.

Workshop Leader: Kevin Killeen, Chief Scientific Officer, Matrivax

-Vaccine Effort Therapies

-Antibiotics: Merck’s DIFICID® (fidaxomicin)



-Fecal Microbiota Transplant

Kevin Killeen, Chief Scientific Officer, Matrivax R & D Corp

Mena Boules, Associate Medical Director, Medical Affairs, Gastroenterology, FERRING Pharmaceuticals

Pamela Sears, Vice President Clinical Science, Merck

Elizabeth Hohmann, Infectious Disease, Massachusetts General Hospital

  • Nicole Ruggiero

Dr. Killeen (CEO) will be presenting at Vaccines Research And Development, November 19, 2019, at the Crowne Plaza Boston.

12:10-12:35 Prophylactic and therapeutic vaccine approach targeting C. difficile infection and relapse. Kevin Killeen, Chief Scientific Officer, Matrivax R&D Corp